Related Experiment Video
Updated: Jun 22, 2026

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
Published on: August 6, 2013
A tragic triad: coronary artery disease, nicotine addiction, and depression
Anne N Thorndike1, Nancy A Rigotti
1General Medicine Division, Tobacco Research and Treatment Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. athorndike@partners.org
Insights
Smokers with cardiovascular disease (CVD) who are depressed are more likely to resume smoking after hospitalization. Intensive, long-term counseling and pharmacotherapy are recommended for smoking cessation in this population.
Area of Science:
- Cardiology
- Psychiatry
- Public Health
Background:
- Continued smoking significantly increases risks for patients with cardiovascular disease (CVD).
- Depression is prevalent in CVD patients and linked to poor adherence to cardiac risk reduction strategies.
- Most smokers with CVD resume smoking post-hospitalization despite available treatments.
Purpose of the Study:
- To review the intricate relationship between smoking and depression in cardiovascular disease (CVD) patients.
- To examine current evidence for interventions targeting this triad of smoking, depression, and CVD.
- To identify effective strategies for smoking cessation in hospitalized CVD patients with depressive symptoms.
Main Methods:
- Systematic review of smoking interventions in hospitalized patients.
- Analysis of secondary data on treatment efficacy for smokers with depression and CVD.
- Literature review on the association between depressive symptoms and smoking relapse in CVD patients.
Main Results:
- Depressive symptoms affect 22-24% of smokers hospitalized with CVD.
- Smokers with depression experience more intense nicotine withdrawal and higher relapse rates.
- Intensive counseling exceeding one month and potentially bupropion SR or CBT show promise for cessation.
Conclusions:
- Screening for depression in CVD smokers, especially during acute events, is crucial.
- Hospitalized CVD smokers require extended (>1 month) intensive counseling for cessation.
- Prolonged treatment, possibly including pharmacotherapy, is needed for depressed CVD smokers to quit smoking.
Purpose Of Review:
Despite the availability of multiple resources for treating smoking in patients with cardiovascular disease (CVD) and the well known risks of continued smoking, a majority of smokers resume smoking after hospitalization for acute CVD. Depression is common among patients with CVD and is associated with failure to follow recommendations to reduce cardiac risk. This review examines the complex relationship between smoking and depression in patients with CVD and current evidence for treating this triad.
Recent Findings:
The prevalence of depressive symptoms among smokers hospitalized with CVD is 22-24%. Smokers with depressive symptoms are more likely to return to smoking after hospital discharge compared with nondepressed smokers. Stronger nicotine withdrawal symptoms among the depressed smokers contribute to relapse. Secondary analyses suggest that bupropion SR and cognitive behavioral therapy may be effective treatments for smokers with depression and CVD. A systematic review of smoking interventions in hospitalized patients found that only intensive counseling interventions with follow-up for more than 1 month were effective for smokers with CVD.
Summary:
Clinicians should consider screening all smokers with CVD for depression, particularly during hospitalization for an acute event. Smokers hospitalized with CVD need intensive counseling lasting more than 1 month after discharge, and smokers with depressive symptoms need even more prolonged treatment for quitting. The addition of pharmacotherapy to long-term counseling has the potential to further improve cessation rates.
Related Concept Videos
CNS Depressants: Alcohol and Nicotine
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome IV: Interprofessional Care
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Stress Prevention and Stress Management Techniques IV
Drug Dependence